课题基金 / 基金详情

The development and clinical application of molecular-based new medical treatments for glaucoma

The development and clinical application of molecular-based new medical treatments for glaucoma
青光眼分子新疗法的开发及临床应用
批准号:
16390500
负责人:
TANIHARA Hidenobu
金额:
$9.22万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2004
资助国家:
日本
项目状态:
已结题
起止时间:
2004 至 2005

项目摘要

项目成果

TANIHARA Hidenobu的其他基金

相似基金

相关文献

中文摘要
翻译
本研究旨在探讨青光眼眼压升高和视神经损害的分子机制,为青光眼的药物治疗提供新的思路。我们展示了手术重建房水流出道的临床结果,以研究房水流出道阻力(Arch Ophthalmol 2004)。然后,我们检查了青光眼的遗传分析,以确定遗传学与房水流出阻力之间的关系(Exp Cell Res 2004 ; IOVS 2004 ; J Glaucoma 2004 ; Mol维斯2005)。此外,我们阐明了淀粉样蛋白诱导的继发性青光眼的分子机制,这是来自一个单一的基因突变。我们报道了突变型甲状腺素运载蛋白在眼组织中的定位、眼部并发症临床治疗的困难以及基因治疗的可能性(Transplantation 2004 ; Gene Therapy 2004 ; Amyloid 2004 ; Exp Eye Res 2005 ; Ophthalmology 2005)。此外,我们研究了ROCK抑制剂对小梁网细胞的药理学作用,该抑制剂可降低房水流出阻力(Exp Eye Res 2006)。另一方面,我们显示了白细胞和内皮细胞之间的相互作用在眼部疾病中的病理学意义,并且显示了相互作用的抑制诱导视网膜组织中的神经保护作用(IOVS 2004 ; Arch Ophthalmol 2004 ; Pro Natl Acad Sci USA,2003)。我们还表明,眼睛在病理条件下表达生物活性因子,也导致神经保护作用(NeuroReport 2004),并且内质网中的应激反应在神经保护中起重要作用(J Neurochem 2006)。
英文摘要
We investigated molecular mechanisms of intraocular pressure elevation and optic nerve damage in glaucoma to develop new medical treatment for glaucoma. We showed the clinical results about surgical reconstruction for aqueous outflow to investigate aqueous outflow resistance (Arch Ophthalmol 2004). Then, we examined genetic analyses of glaucoma to identify the relationship between the genetics and the aqueous outflow resistance (Exp Cell Res 2004 ; IOVS 2004 ; J Glaucoma 2004 ; Mol Vis 2005). In addition, we elucidated the molecular mechanism of amyloid-induced secondary glaucoma, which is derived from a single gene mutation. We reported the localization of mutant transthyretin in ocular tissues, the difficulties in clinical treatments for the ocular complications and the possibility of the gene therapy (Transplantation 2004 ; Gene Therapy 2004 ; Amyloid 2004 ; Exp Eye Res 2005 ; Ophthalmology 2005). Moreover, we investigated the pharmacologic effect of ROCK inhibitor, which reduces the aqueous outflow resistance, for trabecular meshwork cells (Exp Eye Res 2006). On the other hand, we showed the pathological significance of the interaction between leukocytes and endothelium in eye diseases, and showed that the inhibition of the interaction induces the neuroprotective effect in retinal tissues (IOVS 2004 ; Arch Ophthalmol 2004 ; Pro Natl Acad Sci USA, 2003). We also showed that the eye in pathological conditions expresses bioactive factors, also resulting in neuroprotective effects (NeuroReport 2004), and that the stress response in endoplasmic reticula plays an important role in neuroprotection (J Neurochem 2006).
期刊论文(58)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1111/j.1471-4159.2005.03502.x
发表时间: 2006-01-01
期刊: JOURNAL OF NEUROCHEMISTRY
影响因子: 4.7
作者: [Awai, M, Koga, T, Tanihara, H]
通讯作者: Tanihara, H
Expression of a chondroitin sulfata proteoglycan, PG-M/versican, during development of rat cornea.
大鼠角膜发育过程中硫酸软骨素蛋白聚糖 PG-M/versican 的表达。
DOI: --
发表时间: 2005
期刊: Current Eye Research 30
影响因子: --
作者: [Awai M, Koga T, Inomata Y, Oyadomari S, Gotoh T, Mori M, Tanihara H., Koga T et al.]
通讯作者: Koga T et al.
Trans-Tenon's retrobulbar triamcinolone injection for macular edema associated with branch retinal vein occlusion remaining after vitrectomy.
Trans-Tenon 球后曲安西龙注射治疗玻璃体切除术后残留的视网膜分支静脉阻塞相关的黄斑水肿。
DOI: --
发表时间: 2005
期刊: American Journal of Ophthalmology 140
影响因子: --
作者: [Kawaji T, Hirata A, Awai N, Takano A, Inomata Y, Fukushima M, Tanihara H.]
通讯作者: Tanihara H.
Autoimmunity against neurofilament protein and its possible association with HLA-DRB1^*1502 allele in glaucoma.
针对神经丝蛋白的自身免疫及其与青光眼中 HLA-DRB1^*1502 等位基因的可能关联。
DOI: --
发表时间: 2005
期刊: Immunology letters 100
影响因子: --
作者: [Awai M, Koga T, Inomata Y, Oyadomari S, Gotoh T, Mori M, Tanihara H., Koga T et al., Araki-Sasaki et al., Kawaji T et al., Kawaji T et al., Araki-Sasaki K et al., Takano A et al., Yano T et al.]
通讯作者: Yano T et al.
共 36 条
    Study on development of new therapeutic methods based on plasticity of trabecular meshwork cells
    • 批准号:
      17K19729
    • 项目类别:
      Grant-in-Aid for Challenging Research (Exploratory)
    • 资助金额:
      $4.08万
    • 财政年份:
      2017
    • 负责人:
      TANIHARA Hidenobu
    • 依托单位:
    Investigation of glaucoma pathology focusing on epigenome and fibrocyte in aqueous humor dynamics and wound healing
    • 批准号:
      17H04351
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $10.9万
    • 财政年份:
      2017
    • 负责人:
      TANIHARA Hidenobu
    • 依托单位:
    4-dimention live imaging of inflamatory cells in conjunctiva after glaucoma surgery
    • 批准号:
      25670735
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.41万
    • 财政年份:
      2013
    • 负责人:
      TANIHARA Hidenobu
    • 依托单位:
    Establishment of therapeutic assessment in glaucoma neuroprotection using live-imaging of axonal transport in optic nerve
    • 批准号:
      23659814
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.33万
    • 财政年份:
      2011
    • 负责人:
      TANIHARA Hidenobu
    • 依托单位:
    国内基金
    海外基金
    Rho-GTPase 通过调控TNTs 组装保障TC-cTECs间线粒体转移促进产后胸腺再生的机制研究
    • 批准号:
      ZCLQN26H0401
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      许勰
    • 依托单位:
    Rho/ROCK2调节周细胞收缩参与慢性脑缺血引起的血管性认知障碍的机制研究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      刘巧艳
    • 依托单位:
    CHRNA9介导Rho/ROCK信号通路促进非小细胞肺癌侵袭、迁移及顺铂耐药的研究
    Rho激酶抑制剂Y-27632对急性高眼压致角膜内皮损伤的保护及促修复作用研究